

the control of the character of Control of the Cont

the expected high volume of Covid-19 vaccine Adverse Drug Reaction (ADRs) and ensure that no details from the ADRs' reaction text are missed.

II.1.6) Information about lots

This contract is divided into lots: no

II.1.7) Total value of the procurement (excluding VAT)

Value excluding VAT: 1 500 000.00 GBP

II.2) Description

II.2.2) Additional CPV code(s)

48000000 Software package and information systems

II.2.3) Place of performance

NUTS code: UK UNITED KINGDOM

II.2.4) Description of the procurement:

The MHRA urgently seeks an Artificial Intelligence (AI) software tool to process the expected high volume of Covid-19 vaccine Adverse Drug Reaction (ADRs) and ensure that no details from the ADRs' reaction text are missed.

II.2.5) Award criteria

Price

II.2.11) Information about options

Options: no

II.2.13) Information about European Union funds

The procurement is related to a project and/or programme financed by European Union funds: no

II.2.14) Additional information

Section IV: Procedure

IV.1) Description

IV.1.1) Type of procedure

Award of a contract without prior publication of a call for competition in the Official Journal of the European Union in the cases listed below

 The procurement falls outside the scope of application of the directive Explanation:

For reasons of extreme urgency under Regulation 32(2)(c) related to the release of a Covid-19 vaccine MHRA have accelerated the sourcing and implementation of a vaccine specific AI tool.

Strictly necessary — it is not possible to retrofit the MHRA's legacy systems to handle the volume of ADRs that will be generated by a Covid-19 vaccine.

Therefore, if the MHRA does not implement the AI tool, it will be unable to process these ADRs effectively. This will hinder its ability to rapidly identify any potential safety issues with the Covid-19 vaccine and represents a direct threat to patient life and public health.

Reasons of extreme urgency — the MHRA recognises that its planned procurement process for the SafetyConnect programme, including the AI tool, would not have concluded by vaccine launch. Leading to a inability to effectively monitor adverse reactions to a Covid-19 vaccine.

Events unforeseeable — the Covid-19 crisis is novel and developments in the search of a Covid-19 vaccine have not followed any predictable pattern so far.

IV.1.3) Information about a framework agreement or a dynamic purchasing system

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: yes

${\sf IV.2)} \ \ \textbf{Administrative information}$

$\label{eq:continuous} IV.2.8) \ \ \textbf{Information about termination of dynamic purchasing system}$

IV.2.9) Information about termination of call for competition in the form of a prior information notice

Section V: Award of contract

A contract/lot is awarded: yes

V.2) Award of contract

V.2.1) Date of conclusion of the contract:

14/09/2020

V.2.2) Information about tenders

Number of tenders received: 1

The contract has been awarded to a group of economic operators: no

V.2.3) Name and address of the contractor

Official name: Genpact (UK) Ltd

Town: London

NUTS code: UK UNITED KINGDOM

Country: United Kinadom

The contractor is an SME: no

V.2.4) Information on value of the contract/lot (excluding VAT)

Total value of the contract/lot: 1 500 000.00 GBP

V.2.5) Information about subcontracting

Section VI: Complementary information

VI.3) Additional information:

VI.4) Procedures for review

VI.4.1) Review body

Official name: Medicines and Healthcare Products Agency

Town: London

Country: United Kingdom

VI.5) Date of dispatch of this notice:

19/10/2020

Other sites managed by the Publications Office

EUR-LexEU WhoiswhoEU PublicationsCORDISEU Open Data PortalView All (...)



Last updated: 17/11/2020 Site map | About TED | Help | Legal notice | Cookies | Contact | Top